Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M, Li J, Li X, Wu D, Montaño Figueroa E, Rodriguez MG, Hou M, Finelli C, Shi HX, Xiao Z, Oliva EN, Gercheva Kyuchukova L, Drummond M, Symeonidis A, Velazquez EJ, Rivoli G, Izquierdo M, Kolekar Y, Spallarossa P, Angelucci E. Sarocchi M, et al. Among authors: izquierdo m. Br J Haematol. 2024 May;204(5):2049-2056. doi: 10.1111/bjh.19316. Epub 2024 Feb 11. Br J Haematol. 2024. PMID: 38343073 Clinical Trial.
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Angelucci E, et al. Among authors: izquierdo m. Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24. Ann Intern Med. 2020. PMID: 32203980 Clinical Trial.
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
Lai YR, Cappellini MD, Aydinok Y, Porter J, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Liu R, Izquierdo M, Lasher J, Govindaraju S, Taher A. Lai YR, et al. Among authors: izquierdo m. Am J Hematol. 2022 Aug;97(8):E281-E284. doi: 10.1002/ajh.26592. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560253 Free article. No abstract available.
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS).
Wali Y, Hassan T, Charoenkwan P, Trompeter S, Tartaglione I, Origa R, Gamberini MR, Viprakasit V, Izquierdo M, Opio S, Roy T, Taher A. Wali Y, et al. Among authors: izquierdo m. Am J Hematol. 2022 Aug;97(8):E292-E295. doi: 10.1002/ajh.26598. Epub 2022 May 31. Am J Hematol. 2022. PMID: 35570412 Free article. Clinical Trial. No abstract available.
Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study.
Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Yao JC, et al. Among authors: izquierdo m. Onco Targets Ther. 2019 Feb 28;12:1717-1728. doi: 10.2147/OTT.S182259. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881026 Free PMC article.
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Forero-Torres A, Chandler JC, Iyer SP, Kanate AS, Quinlan M, Hoever P, Izquierdo M, Davis J, Madan S. Forero-Torres A, et al. Among authors: izquierdo m. Clin Pharmacol Drug Dev. 2022 Sep;11(9):1099-1109. doi: 10.1002/cpdd.1133. Epub 2022 Jul 12. Clin Pharmacol Drug Dev. 2022. PMID: 35819310 Clinical Trial.
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Lim HY, Melichar B, Zemanova M, Rini B, Choueiri TK, Wood L, Reaume MN, Stenzl A, Chowdhury S, McDermott R, Michael A, Izquierdo M, Aimone P, Zhang H, Sternberg CN; PROTECT study investigators. Motzer RJ, et al. Among authors: izquierdo m. Eur Urol. 2021 Mar;79(3):334-338. doi: 10.1016/j.eururo.2020.12.029. Epub 2021 Jan 15. Eur Urol. 2021. PMID: 33461782 Free PMC article. Clinical Trial.
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O'Connell P, Izquierdo M, Pedroncelli AM, Pivonello R. Fleseriu M, et al. Among authors: izquierdo m. Pituitary. 2022 Dec;25(6):959-970. doi: 10.1007/s11102-022-01280-6. Epub 2022 Oct 11. Pituitary. 2022. PMID: 36219274 Free PMC article. Clinical Trial.
1,214 results